Dasatinib inhibits multiple tyrosine kinases, including BCR-ABL, SRC family, c-KIT, EPHA2 and PDGFRΒ. Dasatinib is predited to bind to multiple confirmations of the ABL kinase.

Recommended dose is 140 mg/day, administered orally in two divided doses of 70 mg. One dose is given in the morning and one in the evening, with or without meals. When administered for chronic phase chronic myeloid leukemia, recommended dose is 100 mg daily.

Indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast-phase chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib.

• Severe bone marrow suppression including neutropenia, thrombocytopenia, anemia.
• Platelet dysfunction may lead to bleeding, highest risk to CNS and GI tract, and mucous membranes.
• Fluid retention, including pleural and pericardial effusion.
• Prolonged QT interval by ECG.
• Diarrhea, nausea, abdominal pain, vomiting

Do not crush or cut tablets. They should be taken whole.

Use with great caution if patients are taking anticoagulants. Drug interactions with CYP3A4 Inducers (eg, dexamethasone, phenytoin, carbamazepine) and substrates (cyclosporine, fentanyl), St. John's wort, antacids, H2 Blockers, and Proton pump inhibitors.

Elevation of transaminases or bilirubin, hypocalcemia and hypophosphatemia. Hypocalcemia may require oral calcium supplements.